Appointment of Steven Bloom as Chief Business Officer brings over 35 years of life sciences industry experience, which could enhance Werewolf's strategic development and business initiatives. Bloom's ...
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for ...
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of ...
Mr. Bloom joins Werewolf from Vincerx Pharma, Inc., where he served as Chief Business Officer. During his time at Vincerx as a member of the executive leadership team focused on business development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results